SEC Company Response from PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Sep 22, 2014
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Sept. 22, 2014 · CIK: 0001095981 · Accession: 0001095981-14-000042
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-34375
Referenced dates: September 19, 2014
Letter
Via Edgarlink and Facsimile Securities and Exchange Commission Division of Corporation Finance RE: Cytori Therapeutics, Inc. (“Cytori”) Form 10-Q for the Quarterly Period Ended June 30, 2014 Filed August 11, 2014 File No. 001-34375
Dear Mr. James:
This letter respond to the comment contained in your letter dated September 19, 2014, regarding our Quarterly Report on Form 10-Q for the period ended June 30, 2014.
For your convenience, we have repeated your comment and set forth our response immediately after the comment. Our response below should not be interpreted as an admission of any deficiency with respect to our Quarterly Report on Form 10-Q for the period ended June 30, 2014.
Note 7. Revenue Recognition, Page 9
1. We note your response to prior comment 6. Please tell us if the change in timing for revenue recognition until cash is collected is applicable to all new customers or only to new customers within Japan. If the new timing applies to all new customers, please tell us the basis for the change in timing for customers outside Japan.
Cytori response: The change in timing for revenue recognition until cash is collected is applicable to all new customers, not only to those in Japan. The basis for changing the timing of revenue recognition for customers that had not developed sufficient payment history with us (and a letter of credit was not in place) at the time of the transaction is due to our recent experience of collectability delays in multiple geographies. An example of this includes the European customer described in response to your prior comment 2. Based on the recent collectability delays experienced for new customers in and outside of Japan, we determined there was a heightened risk of collectability and it was appropriate to change the timing for revenue recognition for all customers that had not developed sufficient payment history with us (and a letter of credit was not in place) at the time of the transaction.
Our response to prior comment 6 was focused on Japan as that has been the majority of our sales activity to new customers. At June 30, 2014, we note the total revenue deferred as a result of this change in timing for revenue recognition for all non-Japanese customers in 2014 is approximately $3,000.
As requested in your comment letter dated September 19, 2014, Cytori hereby acknowledges that:
·
Cytori is responsible for the adequacy and accuracy of the disclosure in the filing;
·
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
·
Cytori may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If I can facilitate the Staff’s review, or if the Staff has any questions on the information set forth herein, please telephone me at (858) 875-5203 or Tiago Girao at (858) 875-5211. Thank you for your time and consideration.
Sincerely,
/s/ Marc H. Hedrick
Show Raw Text
CORRESP
1
filename1.htm
cytori_092214.htm
September 22, 2014
Via Edgarlink and Facsimile
Mr. Martin James
Senior Assistant Chief Accountant
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE: Cytori Therapeutics, Inc. (“Cytori”)
Form 10-Q for the Quarterly Period Ended June 30, 2014
Filed August 11, 2014
File No. 001-34375
Dear Mr. James:
This letter respond to the comment contained in your letter dated September 19, 2014, regarding our Quarterly Report on Form 10-Q for the period ended June 30, 2014.
For your convenience, we have repeated your comment and set forth our response immediately after the comment. Our response below should not be interpreted as an admission of any deficiency with respect to our Quarterly Report on Form 10-Q for the period ended June 30, 2014.
Note 7. Revenue Recognition, Page 9
1. We note your response to prior comment 6. Please tell us if the change in timing for revenue recognition until cash is collected is applicable to all new customers or only to new customers within Japan. If the new timing applies to all new customers, please tell us the basis for the change in timing for customers outside Japan.
Cytori response: The change in timing for revenue recognition until cash is collected is applicable to all new customers, not only to those in Japan. The basis for changing the timing of revenue recognition for customers that had not developed sufficient payment history with us (and a letter of credit was not in place) at the time of the transaction is due to our recent experience of collectability delays in multiple geographies. An example of this includes the European customer described in response to your prior comment 2. Based on the recent collectability delays experienced for new customers in and outside of Japan, we determined there was a heightened risk of collectability and it was appropriate to change the timing for revenue recognition for all customers that had not developed sufficient payment history with us (and a letter of credit was not in place) at the time of the transaction.
Our response to prior comment 6 was focused on Japan as that has been the majority of our sales activity to new customers. At June 30, 2014, we note the total revenue deferred as a result of this change in timing for revenue recognition for all non-Japanese customers in 2014 is approximately $3,000.
As requested in your comment letter dated September 19, 2014, Cytori hereby acknowledges that:
·
Cytori is responsible for the adequacy and accuracy of the disclosure in the filing;
·
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
·
Cytori may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If I can facilitate the Staff’s review, or if the Staff has any questions on the information set forth herein, please telephone me at (858) 875-5203 or Tiago Girao at (858) 875-5211. Thank you for your time and consideration.
Sincerely,
/s/ Marc H. Hedrick
Marc H. Hedrick
President & Chief Executive Officer
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121